Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D Ross Camidge

Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial

The Lancet Oncology

English

Summary Report 7th Annual Targeted Therapies of the Treatment of Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Related publications

Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer

Thoracic Cancer

Respiratory Medicine

English

How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?

Journal of Thoracic Oncology

Respiratory Medicine

English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology

Cancer Research

English

Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer

Cancer Research

Respiratory Medicine

English

Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor

Clinical Cancer Research

Cancer Research

English

Crizotinib in MET Deregulated or ROS1 Rearranged Pretreated Non-Small-Cell Lung Cancer (METROS): A Phase II, Prospective, Multicentre, Two-Arms Trial

Clinical Cancer Research

Cancer Research

English

Alectinib in Untreated Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Annals of Translational Medicine

English

P3.15-31 Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient With IHC-Positive and FISH-Negative ALK

Journal of Thoracic Oncology

Respiratory Medicine

English